Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 17 May 2022
Valneva receives notice of European Commission’s intent to terminate COVID-19 vaccine purchase agreement
16 May 2022 - Valneva today announced that it has received a notice from the European Commission of intent to ...
Posted by Michael Wonder on 17 May 2022
Discount rate adjustment for the health of future generations
17 May 2022 - Medicines Australia has released a video detailing the need for Australia to adjust its discount rate ...
Posted by Michael Wonder on 16 May 2022
Pfizer settles two lawsuits, starts another over etanercept biosimilar in Australia
17 May 2022 - After agreeing to settle with Amgen over its oncology biosimilars, Pfizer issued a new patent lawsuit ...
Posted by Michael Wonder on 16 May 2022
Korea clears permit for Samsung Bioepis’ Lucentis biosimilar after US
16 May 2022 - Samsung Bioepis received marketing approval for Amelivu (ranibizumab), a biosimilar referencing Lucentis to treat various eye ...
Posted by Michael Wonder on 16 May 2022
EMA publishes agenda for 16-19 May 2022 CHMP meeting
16 May 2022 - The EMA has published a draft agenda for this week's CHMP meeting. ...
Posted by Michael Wonder on 16 May 2022
Sun Pharma announces US FDA approval for generic mesalamine extended release capsules
12 May 2022 - Sun Pharmaceutical Industries today announced that it has received final approval from U.S. FDA for its ...
Posted by Michael Wonder on 16 May 2022
Japan pharma lobbies say pricing scheme leading to renewed 'drug lag'
16 May 2022 - Japan's three major pharmaceutical lobbies joined for the first time on Monday in urging reforms to ...
Posted by Michael Wonder on 16 May 2022
AARP ‘people’s hearing’ will highlight Rx struggles
16 May 2022 - Congress will hear how high prescription drug prices affect older Americans. ...
Posted by Michael Wonder on 16 May 2022
FDA rejects anti-depressant seen as possible COVID-19 treatment
16 May 2022 - The FDA declined Monday to authorise a 30 year old generic anti-depressant as a treatment for ...
Posted by Michael Wonder on 16 May 2022
More than 400 people could benefit from life-extending advanced lung cancer treatment after it was recommended for routine use on the NHS
16 May 2022 - Durvalumab recommended as an option for treating non-small-cell lung cancer. ...
Posted by Michael Wonder on 16 May 2022
Tepmetko is granted a temporary subsidy
16 May 2022 - TLV has decided that Tepmetko (tepotinib) shall be included in the high-cost protection until the ordinary subsidy ...
Posted by Michael Wonder on 16 May 2022
Insulin producers face fresh lawsuit in US over pricing
13 May 2022 - Arkansas has become the latest US state to issue a legal challenge to the big three ...
Posted by Michael Wonder on 16 May 2022
Spravato approved for reimbursement in Ireland for adults with treatment-resistant major depressive disorder
16 May 2022 - Janssen has announced that Spravato (esketamine) nasal spray has been granted reimbursement in Ireland for the ...
Posted by Michael Wonder on 16 May 2022
Pfizer and BioNTech provide update on COVID-19 vaccine supply agreement with European Commission
13 May 2022 - May 13, 2022 — Pfizer and BioNTech today announced they have reached an agreement with the European ...
Posted by Michael Wonder on 16 May 2022
Travere Therapeutics announces FDA acceptance and priority review of new drug application for sparsentan for the treatment of IgA nephropathy
16 May 2022 - PDUFA target action date of 17 November 2022. ...